{"id":100735,"date":"2026-11-01T01:01:00","date_gmt":"2026-10-31T19:31:00","guid":{"rendered":"https:\/\/jocr.co.in\/wp\/2026\/11\/synovial-sarcoma-of-the-tibial-nerve-in-the-distal-leg-a-case-of-diagnostic-ambiguity-and-multimodal-management-protocol-for-limb-salvage-and-nerve-reconstruction-a-case-report\/"},"modified":"2026-11-01T01:01:00","modified_gmt":"2026-10-31T19:31:00","slug":"synovial-sarcoma-of-the-tibial-nerve-in-the-distal-leg-a-case-of-diagnostic-ambiguity-and-multimodal-management-protocol-for-limb-salvage-and-nerve-reconstruction-a-case-report","status":"publish","type":"post","link":"https:\/\/jocr.co.in\/wp\/2026\/11\/synovial-sarcoma-of-the-tibial-nerve-in-the-distal-leg-a-case-of-diagnostic-ambiguity-and-multimodal-management-protocol-for-limb-salvage-and-nerve-reconstruction-a-case-report\/","title":{"rendered":"Synovial Sarcoma of the Tibial Nerve in the Distal Leg: A Case of Diagnostic Ambiguity and Multimodal Management Protocol for Limb Salvage and Nerve Reconstruction &#8211; A Case Report"},"content":{"rendered":"<script type='text\/javascript' src='https:\/\/d1bxh8uas1mnw7.cloudfront.net\/assets\/embed.js'><\/script><h2>Introduction<\/h2>\n<p>We present the case of a patient with a rare synovial sarcoma (SS) of the tibial nerve. So far, only 4 cases of patients with SS originating from the tibial nerve have been described in the literature [<a href=\"#R1\">1<\/a>, <a href=\"#R2\">2<\/a>, <a href=\"#R3\">3<\/a>, <a href=\"#R4\">4<\/a>, <a href=\"#R5\">5<\/a>].<\/p>\n<h2>Case Report<\/h2>\n<p>On date July 09, 2024, a 17-year-old male presented with a 1-day history of acute-onset, sharp, shooting pain in the left calf, radiating along the plantar aspect of the left foot. On physical examination, the patient exhibited an antalgic gait with the left foot maintained in an equinus posture.<\/p>\n<p>Palpation revealed a markedly tender mass measuring approximately 3 cm \u00d7 1 cm located in the posteromedial compartment of the left leg, situated deep to the investing fascia along the anatomical course of the tibial nerve. Passive dorsiflexion of the left ankle elicited severe pain. Neurological assessment demonstrated hypoesthesia within the tibial nerve sensory distribution; no focal motor deficits were identified in the left lower extremity. Baseline functional evaluation using the Musculoskeletal Tumor Society (MSTS) scoring system yielded a score of 5\/30 (16.7%) on Day 1 (<a href=\"#T1\" class=\"jxi-fig-ref\">Table 1<\/a>).<\/p>\n<div class=\"jxi-table-wrap\"  orientation=\"portrait\" id=\"T1\" position=\"float\">\nTable 1<\/p>\n<p>MSTS score breakdown<\/p>\n<div class=\"table-responsive\">\n<table class='table'  frame=\"hsides\" rules=\"all\" width=\"100%\">\n<thead>\n<tr>\n<th align=\"center\">Category<\/th>\n<th align=\"center\">Finding<\/th>\n<th align=\"center\">Initial Date July 09, 2024<\/th>\n<th align=\"center\">Follow-up at 2 years and 4 months<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td align=\"center\">Pain<\/td>\n<td align=\"center\">No pain<\/td>\n<td align=\"center\">0<\/td>\n<td align=\"center\">5<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">Function<\/td>\n<td align=\"center\">Recreational restriction<\/td>\n<td align=\"center\">0<\/td>\n<td align=\"center\">3<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">Emotional acceptance<\/td>\n<td align=\"center\">Intermediate (satisfied)<\/td>\n<td align=\"center\">2<\/td>\n<td align=\"center\">3<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">Supports<\/td>\n<td align=\"center\">No support<\/td>\n<td align=\"center\">1<\/td>\n<td align=\"center\">5<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">Walking<\/td>\n<td align=\"center\">Intermediate<\/td>\n<td align=\"center\">1<\/td>\n<td align=\"center\">3<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">Gait<\/td>\n<td align=\"center\">Intermediate<\/td>\n<td align=\"center\">1<\/td>\n<td align=\"center\">3<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">Total raw score<\/td>\n<td align=\"center\"><\/td>\n<td align=\"center\">May-30<\/td>\n<td align=\"center\">22\/30<\/td>\n<\/tr>\n<tr>\n<td align=\"center\">Percentage<\/td>\n<td align=\"center\"><\/td>\n<td align=\"center\">16.6<\/td>\n<td align=\"center\">73.3<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p><strong>MSTS: Musculoskeletal tumor society<\/strong><\/p>\n<\/div>\n<p>Plain radiographs of the left lower extremity revealed no significant osseous abnormalities. Subsequent ultrasonography demonstrated a well-defined, hypoechoic, solid mass within the tibial nerve measuring 24 \u00d7 19 \u00d7 14 mm, raising suspicion for a peripheral nerve sheath tumor. Magnetic resonance imaging (MRI) of the left leg further characterized a well-demarcated, T2-weighted hyperintense lesion measuring 14 \u00d7 15 \u00d7 25 mm within the posteromedial compartment. The mass was anatomically continuous with the tibial nerve, highly suggestive of a benign neurogenic tumor, most likely a schwannoma (<a href=\"#F1\" class=\"jxi-fig-ref\">Fig. 1<\/a>).<\/p>\n<figure id=\"F1\" class=\"jxi-figure\"><img width=\"580\" height=\"683\" src=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF1-converted-1.jpg\" class=\"jxi-figure-img\" alt=\"Figure 1: Magnetic resonance imaging left leg T2-weighted images dated on July 10, 2024, showing a well-demarcated, well-circumscribed hyper intensed lesion of size (14 &#xD7; 15 &#xD7; 25) mm in the course of the tibial nerve.\" decoding=\"async\" loading=\"lazy\" srcset=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF1-converted-1.jpg 580w, https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF1-converted-1-255x300.jpg 255w\" sizes=\"auto, (max-width: 580px) 100vw, 580px\" \/><figcaption>Figure 1: Magnetic resonance imaging left leg T2-weighted images dated on July 10, 2024, showing a well-demarcated, well-circumscribed hyper intensed lesion of size (14 &amp;#xD7; 15 &amp;#xD7; 25) mm in the course of the tibial nerve.<\/figcaption><\/figure>\n<p>On August 07, 2024, the patient was scheduled for a total excisional biopsy of the mass. The procedure was initiated through a short longitudinal skin incision placed over the lesion along the course of the tibial nerve. However, intraoperative exploration revealed an unencapsulated, poorly demarcated mass. Consequently, the planned excision was aborted; instead, a representative incisional biopsy was obtained for histopathological evaluation, and definitive surgical management was deferred.<\/p>\n<p>\u201cOn August 10, 2024, the histopathological examination revealed a cellular lesion composed of spindle-shaped cells arranged in classic Verocay bodies, consistent with a benign schwannoma (<a href=\"#F2\" class=\"jxi-fig-ref\">Fig. 2<\/a>). There was no evidence of histological malignancy.\u201d<\/p>\n<figure id=\"F2\" class=\"jxi-figure\"><img width=\"564\" height=\"524\" src=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF2-converted-1.jpg\" class=\"jxi-figure-img\" alt=\"Figure 2: Ultrasonography-guided biopsy which showed schwannoma. Two growth patterns (1) Antoni A &#x2013; Nuclear palisading region, (2) Antoni B - Less cellular fibrous region. Slide shows prominent Antoni B region.\" decoding=\"async\" loading=\"lazy\" srcset=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF2-converted-1.jpg 564w, https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF2-converted-1-300x279.jpg 300w\" sizes=\"auto, (max-width: 564px) 100vw, 564px\" \/><figcaption>Figure 2: Ultrasonography-guided biopsy which showed schwannoma. Two growth patterns (1) Antoni A &amp;#x2013; Nuclear palisading region, (2) Antoni B &#8211; Less cellular fibrous region. Slide shows prominent Antoni B region.<\/figcaption><\/figure>\n<p>\u201cTo seek an expert second opinion, the patient\u2019s histopathological tissue block was referred to an external pathologist. The subsequent review on August 22, 2024, described a markedly cellular spindle cell neoplasm with malignant and sarcomatous features (<a href=\"#F3\" class=\"jxi-fig-ref\">Fig. 3<\/a>), favoring a malignant diagnosis over a benign process.\u201d<\/p>\n<figure id=\"F3\" class=\"jxi-figure\"><img width=\"564\" height=\"524\" src=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF3-converted-1.jpg\" class=\"jxi-figure-img\" alt=\"Figure 3: Histopathological examination reported as a spindle cell neoplasm sarcomatous in nature.\" decoding=\"async\" loading=\"lazy\" srcset=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF3-converted-1.jpg 564w, https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF3-converted-1-300x279.jpg 300w\" sizes=\"auto, (max-width: 564px) 100vw, 564px\" \/><figcaption>Figure 3: Histopathological examination reported as a spindle cell neoplasm sarcomatous in nature.<\/figcaption><\/figure>\n<p>Subsequent immunohistochemical analysis was performed for definitive classification.\u201d<\/p>\n<div class=\"jxi-subsection\">\n<h4>Combined case narrative (full sequence so far)<\/h4>\n<p>\u201cOn August 07, 2024, the patient was scheduled for a total excisional biopsy of the mass. The procedure commenced with a short longitudinal incision over the lesion along the course of the tibial nerve. However, intraoperative exploration revealed an unencapsulated, poorly demarcated mass, prompting the abandonment of total excision. Instead, a representative incisional biopsy was obtained, and definitive surgical management was deferred.<\/p>\n<p>Initial histopathological evaluation on August 10, 2024, suggested a benign schwannoma characterized by spindle cells forming Verocay bodies (<a href=\"#F2\" class=\"jxi-fig-ref\">Fig. 2<\/a>). To obtain an expert second opinion, the tissue block was referred to an external pathologist. The revised report on August 22, 2024, described a markedly cellular spindle cell neoplasm with sarcomatous features (<a href=\"#F3\" class=\"jxi-fig-ref\">Fig. 3<\/a>), favoring malignancy over a benign process. A comprehensive immunohistochemical study was subsequently performed to further characterize the lesion.\u201d<\/p>\n<\/div>\n<div class=\"jxi-subsection\">\n<h4>Immunohistochemical and molecular findings<\/h4>\n<p>Immunohistochemical analysis supported the diagnosis of SS (<a href=\"#F4\" class=\"jxi-fig-ref\">Fig. 4<\/a>), demonstrating strong positivity for epithelial membrane antigen (EMA) and TLE1 (<a href=\"#F5\" class=\"jxi-fig-ref\">Fig. 5<\/a>), alongside focal\/patchy immunoreactivity for CD99 and pan-keratin. Molecular testing was positive for the SS18::SSX fusion protein product, confirming the pathognomonic balanced translocation t(X;18) (p11.2;q11.2) <sup>[<a href=\"#R6\">6<\/a>]<\/sup>.<\/p>\n<figure id=\"F4\" class=\"jxi-figure\"><img width=\"563\" height=\"524\" src=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF4-converted-1.jpg\" class=\"jxi-figure-img\" alt=\"Figure 4: Immunohistochemistry report: Synovial sarcoma diagnosis.\" decoding=\"async\" loading=\"lazy\" srcset=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF4-converted-1.jpg 563w, https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF4-converted-1-300x279.jpg 300w\" sizes=\"auto, (max-width: 563px) 100vw, 563px\" \/><figcaption>Figure 4: Immunohistochemistry report: Synovial sarcoma diagnosis.<\/figcaption><\/figure>\n<figure id=\"F5\" class=\"jxi-figure\"><img width=\"564\" height=\"525\" src=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF5-converted-1.jpg\" class=\"jxi-figure-img\" alt=\"Figure 5: Immunohistochemical transducing &#x2013; like enhancer 1 &#x2013; almost diagnostic for synovial sarcoma.\" decoding=\"async\" loading=\"lazy\" srcset=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF5-converted-1.jpg 564w, https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF5-converted-1-300x279.jpg 300w\" sizes=\"auto, (max-width: 564px) 100vw, 564px\" \/><figcaption>Figure 5: Immunohistochemical transducing &amp;#x2013; like enhancer 1 &amp;#x2013; almost diagnostic for synovial sarcoma.<\/figcaption><\/figure>\n<p>Alternative spindle cell malignancies were excluded based on negative staining for CD34 (solitary fibrous tumor), S100 and SOX10 (malignant peripheral nerve sheath tumor and melanocytic neoplasms), and desmin (rhabdomyosarcoma\/leiomyosarcoma\/desmoplastic spindle cell neoplasms) <sup>[<a href=\"#R6\">6<\/a>]<\/sup>.<\/p>\n<p>The Ki-67 proliferation index evaluates cellular proliferation by quantifying the percentage of actively dividing tumor cells <sup>[<a href=\"#R7\">7<\/a>]<\/sup>. In the present case, the patient exhibited a Ki-67 index of approximately 20%, markedly exceeding the established prognostic threshold of 9\u201310% <sup>[<a href=\"#R8\">8<\/a>]<\/sup>. Ki-67 expression above this cutoff correlates significantly with an increased risk of local recurrence, disease progression, and decreased metastasis-free survival <sup>[<a href=\"#R9\">9<\/a>]<\/sup>.<\/p>\n<p>On September 05, 2024, a whole-body fluorodeoxyglucose (FDG) positron emission tomography and contrast-enhanced computed tomography (CT) scan was performed for disease staging. The scan revealed a well-defined, enhancing intramuscular soft-tissue mass in the posterior compartment of the left lower leg measuring approximately 1.5 \u00d7 1.2 cm, demonstrating heterogeneous FDG avidity with a maximum standardized uptake value (SUVmax 4.05).<\/p>\n<p>Based on the F\u00e9d\u00e9ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC) histologic grading system for soft-tissue sarcomas and the findings in these pathology reports of the patient, this tumor classified as FNCLCC Grade 2 (Intermediate).<\/p>\n<p>All SSs receive a mandatory differentiation of Score 3 (Tumor Differentiation).<\/p>\n<p>Biopsy notes: \u201cOnly occasional mitosis present\u201d (Ki-67 proliferation index ~20%). Occasional mitoses correlate to &lt;10 mitoses\/10 HPF (Score 1 = 0\u20139 mitoses\/10 HPF). Score 1 (Mitotic Count).<\/p>\n<p>Gross and microscopic examinations show cystic cavity\/foci of hemorrhage and foreign body giant cell reaction, but report no frank tumor necrosis (Score 0 = 0% necrosis). Score 0 (Tumor Necrosis).<\/p>\n<p>\u2022 Total cumulative score: 3 + 1 + 0 = 4<\/p>\n<p>\u2022 FNCLCC grade: Grade 2 (Total score of 4 or 5 corresponds to Grade 2; Grade 1 is 2\u20133, Grade 3 is 6\u20138).<\/p>\n<p>Based on the TNM staging system, the lesion was classified as Stage IIA (G2 T1 N0 M0) <sup>[<a href=\"#R10\">10<\/a>]<\/sup>. Histopathologic examination and Ki-67 immunohistochemical evaluation confirmed an intermediate-to-high grade tumor (G2). MRI revealed an intercompartmental neoplasm along the course of the tibial nerve measuring &lt;5 cm (T1), with no regional lymph node involvement (N0) and no evidence of distant metastasis on PET imaging (M0) <sup>[<a href=\"#R11\">11<\/a>]<\/sup>.<\/p>\n<p>The surgical plan aimed for limb preservation through a wide resection with clear margins, including excision of the previous surgical scar. Through a longitudinal incision incorporating the scar island (<a href=\"#F6\" class=\"jxi-fig-ref\">Fig. 6a<\/a>), a wide-margin excision was performed. The resected specimen included a segment of the tibial nerve along with a cuff of normal surrounding tissue, achieving surgical margins of 1.8 cm superiorly, 1.0 cm inferiorly, 1.0 cm medially, 0.8 cm laterally, and 0.5 cm at the deep base. Histopathological examination confirmed R0 tumor-free margins in all directions.<\/p>\n<figure id=\"F6\" class=\"jxi-figure\"><img width=\"584\" height=\"336\" src=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF6-converted-1.jpg\" class=\"jxi-figure-img\" alt=\"Figure 6: Surgical incision. (a) Surgical incision incorporating previous surgery scar for wide marginal excision of tibial nerve planned on date August 28, 2024. (b) 2 years and 4 months follow-up clinical picture shows cavus foot with clawing of toes, healed neurocutaneous rotational flap.\" decoding=\"async\" loading=\"lazy\" srcset=\"https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF6-converted-1.jpg 751w, https:\/\/jocr.co.in\/wp\/wp-content\/uploads\/20FF6-converted-1-300x173.jpg 300w\" sizes=\"auto, (max-width: 584px) 100vw, 584px\" \/><figcaption>Figure 6: Surgical incision. (a) Surgical incision incorporating previous surgery scar for wide marginal excision of tibial nerve planned on date August 28, 2024. (b) 2 years and 4 months follow-up clinical picture shows cavus foot with clawing of toes, healed neurocutaneous rotational flap.<\/figcaption><\/figure>\n<p>For reconstruction, a sural nerve cable graft harvested from the contralateral leg was used for end-to-end fascicular coaptation to bridge the proximal and distal ends of the resected tibial nerve. Soft-tissue coverage of the primary defect was achieved using a distally based neurovascular sural pedicled neurocutaneous local flap. A split-thickness skin graft was then applied to cover the donor site and any remaining open areas. All surgical wounds healed uneventfully within 20 days.<\/p>\n<p>Postoperatively, adjuvant radiation therapy was indicated due to multiple high-risk clinicopathologic features:<\/p>\n<p>\u2022 Histopathologic nature: SS is an aggressive, high-grade malignancy with a high propensity for local recurrence and distant metastasis.<\/p>\n<p>\u2022 Tumor depth: The lesion was situated deep to the deep fascia, which independently increases the risk of recurrence.<\/p>\n<p>\u2022 Surgical margins: Although an R0 resection was achieved, the basal margin was close at 0.5 cm (&lt;1.0 cm), warranting adjuvant irradiation to optimize local control.<\/p>\n<p>Consequently, the patient received adjuvant radiotherapy with a total dose of 64 Gy delivered in 32 daily fractions.<\/p>\n<p>In accordance with the EORTC 62931 trial (\u201cAdjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma: a multicenter randomised controlled trial\u201d), the absolute overall survival benefit of adjuvant anthracycline and ifosfamide in localized soft-tissue sarcoma is not sufficient to outweigh the substantial risks of treatment-related morbidity <sup>[<a href=\"#R12\">12<\/a>]<\/sup>.<\/p>\n<p>At the 28-month post-operative follow-up, the patient remained pain-free but demonstrated a pes cavus deformity with clawing of the toes and a mildly altered gait (<a href=\"#F6\" class=\"jxi-fig-ref\">Fig. 6b<\/a>). Physical examination revealed mild, functionally non-limiting sensory blunting, an absent ipsilateral Achilles tendon reflex, and intrinsic foot muscle weakness (MRC grade 4\/5 for toe abduction and adduction). The MSTS functional score <sup>[<a href=\"#R10\">10<\/a>]<\/sup> was 22\/30 (73.3%), corresponding to a \u201cGood\u201d clinical outcome (<a href=\"#T1\" class=\"jxi-fig-ref\">Table 1<\/a>).<\/p>\n<p>Follow-up imaging \u2013 including soft-tissue sonography, MRI, and chest X-ray \u2013 revealed no abnormalities.<\/p>\n<\/div>\n<h2>Discussion<\/h2>\n<p>Sss are malignant mesenchymal tumors, arising from connective tissue, schwannomas, neurofibromas, or malignant tumors arise from Schwann cells. A perineurium forms the second envelop, made up of epithelioid cells, from which perineurinomas can arise. The last sheath is the epineurium, formed by fibrous tissue and mesenchymal cells, and from where sarcomas can originate <sup>[<a href=\"#R13\">13<\/a>]<\/sup>. SSs account for 5\u201310% of all soft-tissue sarcomas <sup>[<a href=\"#R14\">14<\/a>]<\/sup>. However, the name SS is misleading, because the tumor does not originate from synovial cells, but rather from primitive mesenchymal cells <sup>[<a href=\"#R11\">11<\/a>]<\/sup>. The name most likely originated from the localization around the large joints on the limbs, more often on the lower ones, in the area of the knee joints <sup>[<a href=\"#R15\">15<\/a>]<\/sup>. There are generally two types of SS. Monophasic sarcoma, i.e., made up of only one type of cells, namely, spindle or glandular cells, and biphasic sarcoma, made up of both types of cells. Soft-tissue sarcomas are usually fast-growing, painless tumors, but SSs often grow more slowly, are painful, can cause joint contractures, swelling, and the average time from the onset of symptoms to the established diagnosis is 2 years <sup>[<a href=\"#R16\">16<\/a>]<\/sup>. Pain was the dominant symptom in our patient as well. SSs often appear in adolescents and young adults, and affects both sexes equally <sup>[<a href=\"#R17\">17<\/a>,<a href=\"#R18\">18<\/a>]<\/sup>. The basis for diagnosis is a magnetic resonance examination and then a biopsy, which should be performed before surgery so that a sufficiently radical procedure can then be performed. Cytogenetically, SS is characterized by the chromosomal translocation t(X;18) (p11.2; q11.2), which leads to the fusion of two genes &#8211; SS18 (SYT) on chromosome 18 and SSX on chromosome X, and to the formation of SYT-SSX fusion transcripts (SS18-: SSX1, SS18-: SSX2, and rarely SS18: -SSX4). Even in our patient, fluorescence in situ hybridization (FISH) analysis confirmed a break in the SS18 gene, testifying to this chromosomal translocation. The immunohistochemical profile of SSs characteristically shows signs of epithelial differentiation.<\/p>\n<p>The detection of pancytokeratins, positive in up to 90% of cases <sup>[<a href=\"#R19\">19<\/a>]<\/sup>, and the expression of the EMA are typical. Both of these markers can be commonly identified in the vast majority of epithelial Tumors <sup>[<a href=\"#R20\">20<\/a>]<\/sup>. EMA positivity itself is non-specific in soft-tissue pathology. The same is true of pancytokeratins <sup>[<a href=\"#R21\">21<\/a>]<\/sup>. Due to this limited specificity (approximate 64\u201385% [pooled average: ~73\u201381%]), TLE1 is recommended as part of an immunohistochemical panel (e.g., with EMA, CD34, BCL2, and keratins) and cannot be considered completely diagnostic on its own <sup>[<a href=\"#R22\">22<\/a>]<\/sup>, while immunohistochemical detection of other proteins (Bcl2, CD56 and CD99) is currently only of limited importance due to low specificity. The focal positivity of the S100 protein can be identified in approximately 1\/3 of SSs <sup>[<a href=\"#R23\">23<\/a>]<\/sup>. S100 protein is a typical marker of neuroectodermal tumors, and a similar focal positivity is often observed in malignant Tumors from peripheral nerve sheaths, which also share a similar spindle cell morphology with SSs. The most reliable means to distinguish between the two units is the proof of a break in the SS18 gene using FISH, reverse transcription polymerase chain reaction, or the massively parallel sequencing method. The main treatment of SS is surgical treatment, which should take place only after a biopsy with histological examination of the tumor so that it is sufficiently radical and does not have to undergo an additional reoperation, as happened in the case of our patient. Primary less radical excision without prior biopsy verification leads to a higher risk of local recurrence, even if a proper re-excision was performed immediately after biopsy verification of the sarcoma <sup>[<a href=\"#R24\">24<\/a>,<a href=\"#R25\">25<\/a>]<\/sup>. Neoadjuvant radiotherapy is recommended especially for larger tumors (&gt;5 cm) or in cases where the resection margin has been reduced, for example due to an ongoing vessel, nerve or bone <sup>[<a href=\"#R26\">26<\/a>]<\/sup>. Radiotherapy seems to prolong the overall survival of patients <sup>[<a href=\"#R27\">27<\/a>,<a href=\"#R28\">28<\/a>,<a href=\"#R29\">29<\/a>]<\/sup>. SSs appear to be more chemo-sensitive than other soft-tissue sarcomas. Chemotherapy is recommended for younger patients or patients with unresectable or already generalized sarcomas <sup>[<a href=\"#R30\">30<\/a>,<a href=\"#R31\">31<\/a>,<a href=\"#R32\">32<\/a>]<\/sup>. Patient\u2019s prognosis is uncertain; reported 5-year survival is around 30\u201350%, and only 10% of patients survive more than 10 years. Negative prognostic factors include tumor invasion into bone or blood vessels, advanced age, larger tumor size, and less radical excision [<a href=\"#R33\">33<\/a>, <a href=\"#R34\">34<\/a>, <a href=\"#R35\">35<\/a>]. Primary insufficiently radical excision increases the risk of local recurrence and thus worse prognosis.<\/p>\n<h2>Conclusion<\/h2>\n<p>This case report draws attention to a rare type of malignant nerve tumor, which both clinically and radiologically can mimic benign peripheral nerve sheath tumors. SS situated under deep fascia is a significant negative prognostic factor which requires a timely diagnosis using MR imaging and a biopsy with histological examination to start treatment quickly.<\/p>\n<blockquote class=\"jxi-boxed-text\">\n<p><strong>Clinical Message<\/strong><\/p>\n<p>Deep-seated soft-tissue masses must be treated with a high index of suspicion for malignancy, regardless of size, and the heterogeneity of the tumor can pose a diagnostic challenge, even for pathologists specializing in sarcoma.<\/p>\n<\/blockquote>\n<div class=\"jxi-subsection\">\n<h4>Conflict of Interest:<\/h4>\n<p>Nil<\/p>\n<\/div>\n<div class=\"jxi-subsection\">\n<h4>Source of Support:<\/h4>\n<p>Nil<\/p>\n<\/div>\n<div class=\"jxi-subsection\">\n<h4>Consent:<\/h4>\n<p>The authors confirm that informed consent was obtained from the patient for publication of this article<\/p>\n<blockquote class=\"jxi-boxed-text\">\n<p><strong>How to Cite this Article<\/strong><\/p>\n<p>Mehta VR, Mehta R, Parmar R, Mehta SR. Synovial Sarcoma of the Tibial Nerve in the Distal Leg: A Case of Diagnostic Ambiguity and Multimodal Management Protocol for Limb Salvage and Nerve Reconstruction &#8211; A Case Report. J Orthop Case Rep 2026 November;16(11): 20-26. doi: 10.13107\/jocr.2026.v16.i11.8374.<\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Introduction We present the case of a patient with a rare synovial sarcoma (SS) of the tibial nerve. So far, only 4 cases of patients with SS originating from the tibial nerve have been described in the literature [1, 2, 3, 4, 5]. Case Report On date July 09, 2024, a 17-year-old male presented with a 1-day history of acute-onset, &hellip; <a href=\"https:\/\/jocr.co.in\/wp\/2026\/11\/synovial-sarcoma-of-the-tibial-nerve-in-the-distal-leg-a-case-of-diagnostic-ambiguity-and-multimodal-management-protocol-for-limb-salvage-and-nerve-reconstruction-a-case-report\/\">Continue reading &hellip;<\/a><\/p>\n","protected":false},"author":1,"featured_media":100724,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[9356],"tags":[546,2014,652,2813,2244,9388],"class_list":["post-100735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-volume-16-issue-11-november-2026","tag-excision","tag-immunohistochemistry","tag-radiotherapy","tag-synovial-sarcoma","tag-tibial-nerve","tag-wide-margin"],"_links":{"self":[{"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/posts\/100735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/comments?post=100735"}],"version-history":[{"count":0,"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/posts\/100735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/media\/100724"}],"wp:attachment":[{"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/media?parent=100735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/categories?post=100735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jocr.co.in\/wp\/wp-json\/wp\/v2\/tags?post=100735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}